ENTITY
BeiGene

BeiGene (6160 HK)

303
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
05 Mar 2020 10:35

A Bottom Has Been Established; Possible Retest?

In today’s report we outline  our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major...

Logo
366 Views
Share
11 Feb 2020 00:32

InnoCare Pharma IPO Initiation: Promising Prognosis

InnoCare Pharma Ltd (1576300D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...

Logo
386 Views
Share
03 Feb 2020 13:37

Akesobio (康方生物) Pre-IPO: Late in the PD-1 Game but Products Are Promising

Akesobio is a clinical-stage biopharmaceutical company with a focus on developing biologics drugs for oncology and autoimmune. The company plans to...

Logo
604 Views
Share
bullishS&P 500 INDEX
20 Dec 2019 06:10

MSCI ACWI, STOXX 600 Breaking Out, Adding Fuel for Further U.S. Equity Market Rally

In today’s report we reiterate our bullish U.S. investment thesis, recap significant technical levels across indexes, and highlight attractive...

Logo
640 Views
Share
25 Nov 2019 13:31

Alibaba IPO/​​​​Secondary Listing Trading - Time to Converge, That's It

Alibaba Group Holding (BABA US) raised around US$13bn (including over-allocation) via a secondary listing in Hong Kong. I've covered various...

Logo
475 Views
Share
x